Jump to contents

Researcher Information

last modified：2026/08/20

Associate Professor　TAKEUCHI, Shinji

Mail

Faculty, Affiliation

University Hospital

College and School Educational Field


Laboratory

Academic Background

Career

(2025/04-)
(2023/09-)
(2021/11-2025/03)
(2020/01-2021/10)
(2016/10-2023/08)
(2009/05-2016/09)
(2008/04-2009/04)
(2007/04-2008/03)
(2006/05-2007/03)
(2004/04-2006/04)
(2003/04-2004/03)

Year & Month of Birth

Academic Society







International Association for the Study of Lung Cancer
European Society For Medical Oncology

Award

European Society For Medical Oncology
European Society For Medical Oncology
European Society For Medical Oncology
European Society For Medical Oncology
○International Session Award(2011/04)

Specialities

Speciality Keywords

Research Themes

Books

Papers

  • 　Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study.　H Sakaguchi,R Katayama,M Matsumoto,A Nishiyama,K Matsumoto,A Tajima,S Miyagi,T Toyama,H Mizuta,K Furugaki,S Yoshiura,S Takeuchi　ESMO open　10　9　105574　2025/09/04
  • 　Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.　Koji Fukuda,Shinji Takeuchi,Sachiko Arai,Shigeki Nanjo,Shigeki Sato,Hiroshi Kotani,Kenji Kita,Akihiro Nishiyama,Hiroyuki Sakaguchi,Koshiro Ohtsubo,Seiji Yano　Cell reports. Medicine　5　6　101578　2024/05/15
  • 　Effect of prior chemotherapy on survival in patients from the randomized phase III J-ALEX study of alectinib versus crizotinib in ALK-positive non-small cell lung cancer　Tetsuya Mitsudomi,Makoto Nishio,Kazuhiko Nakagawa,Nobuyuki Yamamoto,Shinji Takeuchi,Ryohei Katayama,Hiroyuki Sakaguchi,Miki Nomura,Takuya Yoshimoto,Tomohide Tamura　International Journal of Lung Cancer　1　3　100050　2026/09
  • 　Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.　Koji Fukuda,Shinji Takeuchi,Sachiko Arai,Ryohei Katayama,Shigeki Nanjo,Azusa Tanimoto,Akihiro Nishiyama,Takayuki Nakagawa,Hirokazu Taniguchi,Takeshi Suzuki,Tadaaki Yamada,Hiroshi Nishihara,Hironori Ninomiya,Yuichi Ishikawa,Satoko Baba,Kengo Takeuchi,Atsushi Horiike,Noriko Yanagitani,Makoto Nishio,Seiji Yano　Cancer research　79　7　1658　2019/04/01
  • 　Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.　Shinji Takeuchi,Tetsunari Hase,Shinobu Shimizu,Masahiko Ando,Akito Hata,Haruyasu Murakami,Takahiro Kawakami,Katsuhiko Nagase,Kenichi Yoshimura,Tadami Fujiwara,Azusa Tanimoto,Akihiro Nishiyama,Sachiko Arai,Koji Fukuda,Nobuyuki Katakami,Toshiaki Takahashi,Yoshinori Hasegawa,Tun Kiat Ko,S Tiong Ong,Seiji Yano　Cancer science　111　2　561　2020/02

show all

  • 　Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET).　Shinji Takeuchi,Noriko Yanagitani,Takashi Seto,Yoshihiro Hattori,Kadoaki Ohashi,Masahiro Morise,Shingo Matsumoto,Kiyotaka Yoh,Koichi Goto,Makoto Nishio,Shizuko Takahara,Takahiro Kawakami,Yasuhito Imai,Kenichi Yoshimura,Azusa Tanimoto,Akihiro Nishiyama,Toshinori Murayama,Seiji Yano　Translational lung cancer research　10　1　314　2021/01
  • 　Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC.　Timothy F Burns,Natraj Reddy Ammakkanavar,Antoine Hollebecque,Dae Ho Lee,Takafumi Koyama,Philippe A Cassier,Antoine Italiano,Ji-Youn Han,Nimit Singhal,Shinji Takeuchi,Rebecca S Heist,Dustin Deming,Alexander Spira,Quincy Chu,Adrian Sacher,Yutaka Fujiwara,Michael J Chisamore,Arthur Xintian You,Samuel C McNeely,Aaron Fink,Aaron Chen,Geoffrey R Oxnard,Melinda D Willard,Yonina R Murciano-Goroff,Konstantin H Dragnev　Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　21　4　103528　2025/11/28
  • 　Efficacy and safety of selpercatinib in patients with RET-altered thyroid cancers: Update of the phase 1/2 study (LIBRETTO-001)　田原信,竹内伸司,竹内伸司,大橋圭明,本間義崇,横田知哉,岩朝勤,森丈治,大森幸枝,清水康　日本内分泌外科学会雑誌　41　4　292　2024　
  • 　Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-mutant lung cancer.　Koji Fukuda,Shigeki Nanjo,Shinji Takeuchi,Turja Chakrabarti,Tyiesha Brown,Sharon Wesley Dev Sahadevan,Sachiko Arai,Shigeki Sato,Hiroshi Kotani,Akihiro Nishiyama,Hiroyuki Sakaguchi,Koushiro Ohtsubo,Hiroaki Taniguchi,Collin M Blakely,Trever G Bivona,Seiji Yano　Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　2025/06/13
  • 　EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.　Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Hiromichi Ebi,Takako Sano,Shigeki Nanjo,Daisuke Ishikawa,Mitsuo Sato,Yoshinori Hasegawa,Yoshitaka Sekido,Seiji Yano　Cancer research　73　8　2428　2013/04/15
  • 　Development and Characterization of a Patient-Derived KIF5B-RET Fusion Lung Adenocarcinoma Cell Line for Subcutaneous and Central Nervous System Tumor Models in Immunodeficient Mice.　Akihiro Nishiyama,Shigeki Sato,Hiroyuki Sakaguchi,Hiroshi Kotani,Kaname Yamashita,Koushiro Ohtsubo,Shigeki Nanjo,Seiji Yano,Keishi Mizuguchi,Hiroko Ikeda,Makiko Yamaguchi,Tamotsu Ishizuka,Satoko Baba,Kengo Takeuchi,Shinji Takeuchi　JTO clinical and research reports　7　8　101026　2026/08
  • 　STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.　Naohiro Yanagimura,Shinji Takeuchi,Koji Fukuda,Sachiko Arai,Azusa Tanimoto,Akihiro Nishiyama,Naohisa Ogo,Hiroyuki Takahashi,Akira Asai,Satoshi Watanabe,Toshiaki Kikuchi,Seiji Yano　NPJ precision oncology　6　1　11　2022/02/28
  • 　Intrinsic Cooperation between p16(INK4a) and p21(Waf1/Cip1) in the Onset of Cellular Senescence and Tumor Suppression In vivo　Shinji Takeuchi,Akiko Takahashi,Noriko Motoi,Shin Yoshimoto,Tomoko Tajima,Kimi Yamakoshi,Atsushi Hirao,Shigeru Yanagi,Kiyoko Fukami,Yuichi Ishikawa,Saburo Sone,Eiji Hara,Naoko Ohtani　CANCER RESEARCH　70　22　9381　2010/11
  • 　Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.　Shinji Takeuchi,Toshinori Murayama,Kenichi Yoshimura,Takahiro Kawakami,Shizuko Takahara,Yasuhito Imai,Yoshikazu Kuribayashi,Katsuhiko Nagase,Koichi Goto,Makoto Nishio,Yoshinori Hasegawa,Miyako Satouchi,Katsuyuki Kiura,Takashi Seto,Seiji Yano　The journal of medical investigation : JMI　64　3.4　317　2017
  • 　Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.　Shinji Takeuchi,Wei Wang,Qi Li,Tadaaki Yamada,Kenji Kita,Ivan S Donev,Takahiro Nakamura,Kunio Matsumoto,Eiji Shimizu,Yasuhiko Nishioka,Saburo Sone,Takayuki Nakagawa,Toshimitsu Uenaka,Seiji Yano　The American journal of pathology　181　3　1034　2012/09
  • 　Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC.　Rajeswara Rao Arasada,Konstantin Shilo,Tadaaki Yamada,Jianying Zhang,Seiji Yano,Rashelle Ghanem,Walter Wang,Shinji Takeuchi,Koji Fukuda,Nobuyuki Katakami,Keisuke Tomii,Fumitaka Ogushi,Yasuhiko Nishioka,Tiffany Talabere,Shrilekha Misra,Wenrui Duan,Paolo Fadda,Mohammad A Rahman,Patrick Nana-Sinkam,Jason Evans,Joseph Amann,Elena E Tchekneva,Mikhail M Dikov,David P Carbone　Nature communications　9　1　3198　2018/08/10
  • 　Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation　Shinji Takeuchi,Koji Fukuda,Tadaaki Yamada,Sachiko Arai,Satoshi Takagi,Genichiro Ishii,Atsushi Ochiai,Shotaro Iwakiri,Kazumi Itoi,Hisanori Uehara,Hiroshi Nishihara,Naoya Fujita,Seiji Yano　CANCER SCIENCE　108　4　696　2017/04
  • 　AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.　Hirokazu Taniguchi,Tadaaki Yamada,Rong Wang,Keiko Tanimura,Yuta Adachi,Akihiro Nishiyama,Azusa Tanimoto,Shinji Takeuchi,Luiz H Araujo,Mariana Boroni,Akihiro Yoshimura,Shinsuke Shiotsu,Isao Matsumoto,Satoshi Watanabe,Toshiaki Kikuchi,Satoru Miura,Hiroshi Tanaka,Takeshi Kitazaki,Hiroyuki Yamaguchi,Hiroshi Mukae,Junji Uchino,Hisanori Uehara,Koichi Takayama,Seiji Yano　Nature communications　10　1　259　2019/01/16
  • 　Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program.　Daisuke Kotani,Atsuo Takashima,Takeshi Kato,Taroh Satoh,Toshiki Masuishi,Yoshito Komatsu,Manabu Shiozawa,Taito Esaki,Naoki Izawa,Shinji Takeuchi,Hideaki Bando,Satoru Iwasa,Hiroko Hasegawa,Toshifumi Yamaguchi,Hiroya Taniguchi,Yasunori Ushida,Toshiya Oizaki,Chiaki Inoue,Takayuki Yoshino　Clinical colorectal cancer　23　2　174　2024/03/09
  • 　FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies.　Yukata Fujiwara,Yasutoshi Kuboki,Masayuki Furukawa,Nobumasa Mizuno,Hiroki Hara,Tatsuya Ioka,Makoto Ueno,Yasuo Takahashi,Shunji Takahashi,Shinji Takeuchi,Christine Lihou,Tao Ji,Chenwei Tian,Toshio Shimizu　Cancer medicine　12　9　10597　2023/03/31
  • 　Challenges in the treatment of BRAF K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib.　Akihiro Nishiyama,Shigeki Sato,Hiroyuki Sakaguchi,Hiroshi Kotani,Kaname Yamashita,Koushiro Ohtsubo,Shigeki Nanjo,Seiji Yano,Keishi Mizuguchi,Hiroko Ikeda,Shinji Takeuchi　Frontiers in oncology　14　1374594　2024
  • 　Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.　Hitomi Koizumi,Tadaaki Yamada,Shinji Takeuchi,Takayuki Nakagawa,Kenji Kita,Takahiro Nakamura,Kunio Matsumoto,Kenichi Suda,Tetsuya Mitsudomi,Seiji Yano　Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　7　7　1078　2012/07
  • 　Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation.　Shinji Takeuchi,Koji Fukuda,Tadaaki Yamada,Sachiko Arai,Satoshi Takagi,Genichiro Ishii,Atsushi Ochiai,Shotaro Iwakiri,Kazumi Itoi,Hisanori Uehara,Hiroshi Nishihara,Naoya Fujita,Seiji Yano　Cancer science　108　4　696　2017/04
  • 　Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.　Rong Wang,Tadaaki Yamada,Kenji Kita,Hirokazu Taniguchi,Sachiko Arai,Koji Fukuda,Minoru Terashima,Akihiko Ishimura,Akihiro Nishiyama,Azusa Tanimoto,Shinji Takeuchi,Koshiro Ohtsubo,Kaname Yamashita,Tomoyoshi Yamano,Akihiro Yoshimura,Koichi Takayama,Kyoichi Kaira,Yoshihiko Taniguchi,Shinji Atagi,Hisanori Uehara,Rikinari Hanayama,Isao Matsumoto,Xujun Han,Kunio Matsumoto,Wei Wang,Takeshi Suzuki,Seiji Yano　Nature communications　11　1　4607　2020/09/14
  • 　Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.　Akihiro Nishiyama,Tadaaki Yamada,Kenji Kita,Rong Wang,Sachiko Arai,Koji Fukuda,Azusa Tanimoto,Shinji Takeuchi,Shoichiro Tange,Atsushi Tajima,Noritaka Furuya,Takayoshi Kinoshita,Seiji Yano　Clinical cancer research : an official journal of the American Association for Cancer Research　24　10　2357　2018/05/15
  • 　MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements.　Yohei Takumi,Sachiko Arai,Chiaki Suzuki,Koji Fukuda,Akihiro Nishiyama,Shinji Takeuchi,Hiroki Sato,Kunio Matsumoto,Kenji Sugio,Seiji Yano　Cancer medicine　12　5　5809　2022/11/23
  • 　Targeted therapy by MET inhibitors against small-cell lung cancer with aberrant activation of HGF/MET pathway　Hirokazu Taniguchi,Shinji Takeuchi,Koji Fukuda,Tadaaki Yamada,Shuichi Sakamoto,Manabu Kawada,Seiji Yano　Cancer science　76　2016/07
  • 　Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.　Tadaaki Yamada,Joseph M Amann,Koji Fukuda,Shinji Takeuchi,Naoya Fujita,Hisanori Uehara,Shotaro Iwakiri,Kazumi Itoi,Konstantin Shilo,Seiji Yano,David P Carbone　Cancer research　75　19　4188　2015/10/01
  • 　[Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective].　Tadaaki Yamada,Koushiro Ohtsubo,Daisuke Ishikawa,Shigeki Nanjo,Shinji Takeuchi,Hisatsugu Mouri,Kaname Yamashita,Kazuo Yasumoto,Seiji Yano　Gan to kagaku ryoho. Cancer & chemotherapy　39　8　1291　2012/08
  • 　Antiangiogenic therapies for malignant pleural mesothelioma.　Seiji Yano,Qi Li,Wei Wang,Tadaaki Yamada,Shinji Takeuchi,Emiko Nakataki,Hirokazu Ogino,Hisatsugu Goto,Yasuhiko Nishioka,Saburo Sone　Frontiers in bioscience (Landmark edition)　16　740　2011/01/01
  • 　Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.　Azusa Tanimoto,Tadaaki Yamada,Shigeki Nanjo,Shinji Takeuchi,Hiromichi Ebi,Kenji Kita,Kunio Matsumoto,Seiji Yano　Oncotarget　5　13　4920　2014/07/15
  • 　Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.　Hirokazu Taniguchi,Shinji Takeuchi,Koji Fukuda,Takayuki Nakagawa,Sachiko Arai,Shigeki Nanjo,Tadaaki Yamada,Hiroyuki Yamaguchi,Hiroshi Mukae,Seiji Yano　Cancer science　108　1　53　2017/01
  • 　Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.　Shinji Takeuchi,Kenichi Yoshimura,Tadami Fujiwara,Masahiko Ando,Shinobu Shimizu,Katsuhiko Nagase,Yoshinori Hasegawa,Toshiaki Takahashi,Nobuyuki Katakami,Akira Inoue,Seiji Yano　The journal of medical investigation : JMI　64　3.4　321　2017
  • 　Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.　Shinji Takeuchi,Koji Fukuda,Sachiko Arai,Shigeki Nanjo,Kenji Kita,Tadaaki Yamada,Eiji Hara,Hiroshi Nishihara,Hisanori Uehara,Seiji Yano　International journal of cancer　138　5　1281　2016/03/01
  • 　Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency.　Koushiro Ohtsubo,Daisuke Ishikawa,Shigeki Nanjo,Shinji Takeuchi,Tadaaki Yamada,Hisatsugu Mouri,Kaname Yamashita,Kazuo Yasumoto,Toshifumi Gabata,Osamu Matsui,Hiroko Ikeda,Yasushi Takamatsu,Sakae Iwakami,Seiji Yano　JOP : Journal of the pancreas　14　5　515　2013/09/10
  • 　mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.　Daisuke Ishikawa,Shinji Takeuchi,Takayuki Nakagawa,Takako Sano,Junya Nakade,Shigeki Nanjo,Tadaaki Yamada,Hiromichi Ebi,Lu Zhao,Kazuo Yasumoto,Takahiro Nakamura,Kunio Matsumoto,Hiroshi Kagamu,Hirohisa Yoshizawa,Seiji Yano　PloS one　8　5　e62104　2013
  • 　Anti-angiogenic therapy for respiratory cancer　Shinji Takeuchi,Seiji Yano　Biotherapy　25　5　834　2011/09/30
  • 　A Supramolecular Biosensor for Rapid and High-Throughput Quantification of a Disease-Associated Niacin Metabolite.　Masaya Ueno,Hiroki Sugiyama,Feng Li,Tatsuya Nishimura,Hiroshi Arakawa,Xi Chen,Xiaoxiao Cheng,Shinji Takeuchi,Yumie Takeshita,Toshinari Takamura,Sakae Miyagi,Tadashi Toyama,Tomoyoshi Soga,Yusuke Masuo,Yukio Kato,Hiroyuki Nakamura,Hiromasa Tsujiguchi,Akinori Hara,Atsushi Tajima,Moeko Noguchi-Shinohara,Kenjiro Ono,Kenta Kurayoshi,Masahiko Kobayashi,Yuko Tadokoro,Atsuko Kasahara,Mahmoud I Shoulkamy,Katsuhiro Maeda,Tomoki Ogoshi,Atsushi Hirao　Analytical chemistry　96　36　14499　2024/08/25
  • 　Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.　Shinji Takeuchi, Tetsunari Hase, Shinobu Shimizu, Masahiko Ando, Akito Hata, Haruyasu Murakami, Takahiro Kawakami, Katsuhiko Nagase, Kenichi Yoshimura, Tadami Fujiwara, Azusa Tanimoto, Akihiro Nishiyama, Sachiko Arai, Koji Fukuda, Nobuyuki Katakami, Toshiaki Takahashi, Yoshinori Hasegawa, Tun Kiat Ko, S Tiong Ong, Seiji Yano　Cancer science　2020/02
  • 　Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.　Rong Wang,Tadaaki Yamada,Sachiko Arai,Koji Fukuda,Hirokazu Taniguchi,Azusa Tanimoto,Akihiro Nishiyama,Shinji Takeuchi,Kaname Yamashita,Koshiro Ohtsubo,Junji Matsui,Naoyoshi Onoda,Eishu Hirata,Shu Taira,Seiji Yano　Molecular cancer therapeutics　18　5　947　2019/05
  • 　Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case Reports.　Hiroyuki Sakaguchi,Shigeki Nanjo,Shigeki Sato,Hiroshi Kotani,Akihiro Nishiyama,Kaname Yamashita,Koushiro Ohtsubo,Chiaki Suzuki,Masaya Shimojima,Seiji Yano,Shinji Takeuchi　Internal medicine (Tokyo, Japan)　2024/09/04
  • 　Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.　Chiaki Suzuki,Akihiro Nishiyama,Sachiko Arai,Shoichiro Tange,Atsushi Tajima,Azusa Tanimoto,Koji Fukuda,Yohei Takumi,Hiroshi Kotani,Shinji Takeuchi,Naohiro Yanagimura,Koushiro Ohtsubo,Norio Yamamoto,Koichi Omori,Seiji Yano　Cancer science　113　7　2323　2022/04/01
  • 　Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: A case study and implications for precision oncology.　Akihiro Nishiyama,Shigeki Sato,Hiroyuki Sakaguchi,Hiroshi Kotani,Kaname Yamashita,Koushiro Ohtsubo,Tomoko Sekiya,Atsushi Watanabe,Atsushi Tajima,Chie Shimaguchi,Keishi Mizuguchi,Hiroko Ikeda,Masashi Kinoshita,Mitsutoshi Nakada,Shinji Takeuchi　Cancer science　116　1　271　2024/10/25
  • 　The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.　Takako Sano,Shinji Takeuchi,Takayuki Nakagawa,Daisuke Ishikawa,Shigeki Nanjo,Tadaaki Yamada,Takahiro Nakamura,Kunio Matsumoto,Seiji Yano　International journal of cancer　133　2　505　2013/07/15
  • 　Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells.　Tadaaki Yamada,Hideaki Bando,Shinji Takeuchi,Kenji Kita,Qi Li,Wei Wang,Shiro Akinaga,Yasuhiko Nishioka,Saburo Sone,Seiji Yano　Cancer science　102　12　2157　2011/12
  • 　E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.　Hirokazu Ogino,Masaki Hanibuchi,Soji Kakiuchi,Van The Trung,Hisatsugu Goto,Kenji Ikuta,Tadaaki Yamada,Hisanori Uehara,Akihiko Tsuruoka,Toshimitsu Uenaka,Wei Wang,Qi Li,Shinji Takeuchi,Seiji Yano,Yasuhiko Nishioka,Saburo Sone　Molecular cancer therapeutics　10　7　1218　2011/07
  • 　Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.　Lu Zhao,Kazuo Yasumoto,Atsuhiro Kawashima,Takayuki Nakagawa,Shinji Takeuchi,Tadaaki Yamada,Kunio Matsumoto,Kazuhiko Yonekura,Osamu Yoshie,Seiji Yano　Cancer science　104　12　1640　2013/12
  • 　Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.　Wei Wang,Qi Li,Shinji Takeuchi,Tadaaki Yamada,Hitomi Koizumi,Takahiro Nakamura,Kunio Matsumoto,Naofumi Mukaida,Yasuhiko Nishioka,Saburo Sone,Takayuki Nakagawa,Toshimitsu Uenaka,Seiji Yano　Clinical cancer research : an official journal of the American Association for Cancer Research　18　6　1663　2012/03/15
  • 　Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.　Tadaaki Yamada,Shinji Takeuchi,Kenji Kita,Hideaki Bando,Takahiro Nakamura,Kunio Matsumoto,Seiji Yano　Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　7　2　272　2012/02
  • 　In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs.　Kenji Kita,Sachiko Arai,Akihiro Nishiyama,Hirokazu Taniguchi,Koji Fukuda,Rong Wang,Tadaaki Yamada,Shinji Takeuchi,Shoichiro Tange,Atsushi Tajima,Mitsutoshi Nakada,Kazuo Yasumoto,Yoshiharu Motoo,Takashi Murakami,Seiji Yano　Cancer medicine　6　12　2972　2017/12
  • 　Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.　Shinji Takeuchi,Seiji Yano　Respiratory investigation　52　6　348　2014/11
  • 　In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET.　Sachiko Arai,Kenji Kita,Azusa Tanimoto,Shinji Takeuchi,Koji Fukuda,Hiroshi Sato,Seiji Yano　Oncotarget　8　43　73766　2017/09/26
  • 　Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway　Hirokazu Taniguchi,Tadaaki Yamada,Shinji Takeuchi,Sachiko Arai,Koji Fukuda,Shuichi Sakamoto,Manabu Kawada,Hiroyuki Yamaguchi,Hiroshi Mukae,Seiji Yano　CANCER SCIENCE　108　7　1378　2017/07
  • 　Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer.　Azusa Tanimoto,Shinji Takeuchi,Sachiko Arai,Koji Fukuda,Tadaaki Yamada,Xavier Roca,S Tiong Ong,Seiji Yano　Clinical cancer research : an official journal of the American Association for Cancer Research　23　12　3139　2017/06/15
  • 　High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.　Shigeki Nanjo,Hiromichi Ebi,Sachiko Arai,Shinji Takeuchi,Tadaaki Yamada,Satsuki Mochizuki,Yasunori Okada,Mitsutoshi Nakada,Takashi Murakami,Seiji Yano　Oncotarget　7　4　3847　2016/01/26
  • 　Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.　Junya Nakade,Shinji Takeuchi,Takayuki Nakagawa,Daisuke Ishikawa,Takako Sano,Shigeki Nanjo,Tadaaki Yamada,Hiromichi Ebi,Lu Zhao,Kazuo Yasumoto,Kunio Matsumoto,Kazuhiko Yonekura,Seiji Yano　Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　9　6　775　2014/06
  • 　Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer.　Koushiro Ohtsubo,Tadaaki Yamada,Lu Zhao,Tie-Feng Jin,Shinji Takeuchi,Hisatsugu Mouri,Kaname Yamashita,Kazuo Yasumoto,Naoya Fujita,Hirohisa Kitagawa,Tetsuo Ohta,Hiroko Ikeda,Seiji Yano　Pancreas　43　7　1093　2014/10
  • 　Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report.　Azusa Tanimoto,Shinji Takeuchi,Hiroshi Kotani,Kaname Yamashita,Tadaaki Yamada,Koushiro Ohtsubo,Hiromichi Ebi,Hiroko Ikeda,Seiji Yano　BMC pulmonary medicine　18　1　193　2018/12/12
  • 　Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.　Sachiko Arai,Shinji Takeuchi,Koji Fukuda,Azusa Tanimoto,Akihiro Nishiyama,Hiroaki Konishi,Akimitsu Takagi,Hiroyuki Takahashi,S Tiong Ong,Seiji Yano　The journal of medical investigation : JMI　67　3.4　343　2020
  • 　Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.　Koji Fukuda,Sakiko Otani,Shinji Takeuchi,Sachiko Arai,Shigeki Nanjo,Azusa Tanimoto,Akihiro Nishiyama,Katsuhiko Naoki,Seiji Yano　Cancer science　112　9　3784　2021/06/19
  • 　Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma.　Akihiro Nishiyama,Hiroyuki Sakaguchi,Naohiro Yanagimura,Chiaki Suzuki,Sakiko Otani,Azusa Tanimoto,Kaname Yamashita,Shinji Takeuchi,Koushiro Ohtsubo,Hiroko Ikeda,Seiji Yano　Oxford medical case reports　2020　12　omaa116　2020/12
  • 　A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.　Hiroyuki Yasuda,Eiki Ichihara,Jun Sakakibara-Konishi,Yoshitaka Zenke,Shinji Takeuchi,Masahiro Morise,Katsuyuki Hotta,Mineyoshi Sato,Shingo Matsumoto,Azusa Tanimoto,Reiko Matsuzawa,Katuyuki Kiura,Yuta Takashima,Seiji Yano,Junji Koyama,Takahiro Fukushima,Junko Hamamoto,Hideki Terai,Shinnosuke Ikemura,Ryo Takemura,Koichi Goto,Kenzo Soejima　Lung cancer (Amsterdam, Netherlands)　162　140　2021/12
  • 　Multi-institutional survey of cancer disparities in disabled patients in the region of northwestern Japan.　Shigeki Sato,Azusa Tanimoto,Naohiro Yanagimura,Chiaki Suzuki,Yohei Takumi,Akihiro Nishiyama,Kaname Yamashita,Shinji Takeuchi,Koushiro Ohtsubo,Tomoe Makino,Yoshio Yoshida,Yasuo Hirono,Ryuji Hayashi,Tomonobu Koizumi,Yozo Nakazawa,Ken-Ichi Ito,Yoshiharu Motoo,Hidetaka Uramoto,Mitsutoshi Nakada,Yoshikazu Nishino,Seiji Yano　International journal of clinical oncology　26　6　1009　2021/03/01
  • 　Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report.　Yuta Adachi,Naohiro Yanagimura,Chiaki Suzuki,Sakiko Ootani,Azusa Tanimoto,Akihiro Nishiyama,Kaname Yamashita,Koushiro Ohtsubo,Shinji Takeuchi,Seiji Yano　BMC cancer　20　1　156　2020/02/24
  • 　MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.　Akihiro Nishiyama,Shinji Takeuchi,Yuta Adachi,Sakiko Otani,Azusa Tanimoto,Motoko Sasaki,Shingo Matsumoto,Koichi Goto,Seiji Yano　Cancer science　111　10　3813　2020/07/31
  • 　Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification.　Makoto Yamamoto,Takeshi Terashima,Tatsuya Yamashita,Akihiro Seki,Hidetoshi Nakagawa,Kouki Nio,Tetsuro Shimakami,Hajime Takatori,Kuniaki Arai,Eishiro Mizukoshi,Masao Honda,Shinji Takeuchi,Taro Yamashita　Hepatology research : the official journal of the Japan Society of Hepatology　54　3　315　2023/10/10
  • 　Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. 　Azusa Tanimoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Tadaaki Yamada, Xavier Roca, S Tiong Ong, Seiji Yano　Clinical cancer research　23　12　3139-3149　2017/06/15
  • 　In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET. 　Sachiko Arai, Kenji Kita, Azusa Tanimoto, Shinji Takeuchi, Koji Fukuda, Hiroshi Sato, Seiji Yano　Oncotarget　8　43　73766-73773　2017/09/26
  • 　Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.　Hirokazu Taniguchi, Tadaaki Yamada, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Shuichi Sakamoto, Manabu Kawada, Hiroyuki Yamaguchi, Hiroshi Mukae, Seiji Yano　Cancer science　108　7　1378-1385　2017/06/08
  • 　In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs.　Kenji Kita, Sachiko Arai, Akihiro Nishiyama, Hirokazu Taniguchi, Koji Fukuda, Rong Wang, Tadaaki Yamada, Shinji Takeuchi, Shoichiro Tange, Atsushi Tajima, Mitsutoshi Nakada, Kazuo Yasumoto, Yoshiharu Motoo, Takashi Murakami, Seiji Yano　Cancer medicine　6　12　2972-2983　2017/11/10
  • 　Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.　Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S　Cancer Research　2019/04/01
  • 　Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.　Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.　Am J Pathol.　181　3　1034-43　2012/07/09
  • 　EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.　Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S.　Cancer Res.　73　8　2428-34　2013/04/15
  • 　Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer.　Takeuchi S, Fukuda K, Arai S, Nanjo S, Kita K, Yamada T, Hara E, Nishihara H, Uehara H, Yano S.　Int J Cancer.　138　5　1281-9　2016/03/01
  • 　High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.　Nanjo S, Ebi H, Arai S, Takeuchi S, Yamada T, Mochizuki S, Okada Y, Nakada M, Murakami T, Yano S.　Oncotarget.　7　4　3847-56　2016/01/26
  • 　Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.　Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S.　Cancer Sci.　108　1　53-60　2016/12/30
  • 　mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.　Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S.　PLoS One.　8　5　e62104　2013/05/14
  • 　Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.　Sachiko Arai,Shinji Takeuchi,Koji Fukuda,Hirokazu Taniguchi,Akihiro Nishiyama,Azusa Tanimoto,Miyako Satouchi,Kaname Yamashita,Koshiro Ohtsubo,Shigeki Nanjo,Toru Kumagai,Ryohei Katayama,Makoto Nishio,Mei-Mei Zheng,Yi-Long Wu,Hiroshi Nishihara,Takushi Yamamoto,Mitsutoshi Nakada,Seiji Yano　Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer　15　5　752　2020/05
  • 　Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practice.　Takeshi Terashima,Tatsuya Yamashita,Kuniaki Arai,Noboru Takata,Tomoyuki Hayashi,Akihiro Seki,Hidetoshi Nakagawa,Kouki Nio,Noriho Iida,Shinya Yamada,Tetsuro Shimakami,Hajime Takatori,Kunihiro Tsuji,Hajime Sunagozaka,Eishiro Mizukoshi,Masao Honda,Shinji Takeuchi,Taro Yamashita　Hepatology international　19　1　212　2024/11/14
  • 　Glycogen synthase kinase-3 inhibition overcomes epithelial-mesenchymal transition-associated resistance to osimertinib in EGFR-mutant lung cancer.　Koji Fukuda,Shinji Takeuchi,Sachiko Arai,Kenji Kita,Azusa Tanimoto,Akihiro Nishiyama,Seiji Yano　Cancer science　111　7　2374　2020/07
  • 　Case report: Navigating treatment pathways for cardiac intimal sarcoma with PDGFRβ N666K mutation.　Akihiro Nishiyama,Shigeki Sato,Hiroyuki Sakaguchi,Hiroshi Kotani,Kaname Yamashita,Koushiro Ohtsubo,Keishi Mizuguchi,Hiroko Ikeda,Kenji Iino,Hirofumi Takemura,Shinji Takeuchi　Frontiers in oncology　14　1362347　2024
  • 　Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.　Azusa Tanimoto,Shingo Matsumoto,Shinji Takeuchi,Sachiko Arai,Koji Fukuda,Akihiro Nishiyama,Kiyotaka Yoh,Takaya Ikeda,Naoki Furuya,Kazumi Nishino,Yuichiro Ohe,Koichi Goto,Seiji Yano　Clinical cancer research : an official journal of the American Association for Cancer Research　27　5　1410　2020/12/11
  • 　Case Report: Medullary carcinoma of the pancreas with MLH1 promoter hypermethylation, induced deficient mismatch repair, successfully treated with an immune checkpoint inhibitor.　Koushiro Ohtsubo,Shigeki Sato,Hiroyuki Sakaguchi,Hiroshi Kotani,Akihiro Nishiyama,Kaname Yamashita,Seiji Yano,Fumihito Toshima,Dai Inoue,Toshifumi Gabata,Hiroko Ikeda,Atsushi Watanabe,Kenji Notohara,Takao Fujisawa,Yoshiaki Nakamura,Takayuki Yoshino,Kunio Miyake,Kazuhiro Miwa,Shinji Takeuchi　Frontiers in oncology　15　1551038　2025

Conference Presentations

Others

Arts and Fieldwork

Patent

Theme to the desired joint research

Grant-in-Aid for Scientific Research

○2022「ALK肺がんのアポトーシス抵抗性因子を標的とした新規治療の開発」(2020-2022)　
○「miR-201sを標的とした肺癌のEMTに起因するTKI耐性克服治療の開発」(2018-2020)　
○「アポトーシス抵抗性に起因する変異型選択的EGFR-TKI耐性克服治療の開発」(2017-2019)　
○「EGFR変異肺癌のアポトーシス抵抗性に起因する次世代型EGFR-TKI耐性の克服」(2017-2019)　
○「EGFR変異肺癌のBIM遺伝子多型に起因するEGFR-TKI耐性克服治療の開発」(2013-2014)
○「Rasシグナル活性化変異を有する原発性肺癌を標的とした新規治療法の開発」(2011-2012)　

Competitive research funding,Contribution

Collaborative research,Consignment study

Classes (Graduate Schools)

○Seminar on Clinical Oncology(2017)
○Seminar on Clinical Oncology(2016)

Classes (Bachelors)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top